03/27/2018
Osteoarthritis–as an immune-mediated disease–should be treated as such. While NSAIDs (nonsteroidal anti-inflammatory drugs) act by reducing pain and swelling, LTCI addresses the underlying cause of osteoarthritis, i.e. the chronic immune-mediated attack on joint tissue. By increasing precursors of regulatory cells, LTCI reduces the immune response directed against the joint, which is the cause of the progressive joint degeneration.
In a pivotal clinical trial, over 90% of LTCI patients achieved significant improvements in symptoms. Learn more on our website:
LTCI is the first and only USDA-approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). And now, LTCI is the first USDA-approved immune modulator for treatment of osteoarthritis in dogs.
